JPWO2020051493A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020051493A5 JPWO2020051493A5 JP2021512773A JP2021512773A JPWO2020051493A5 JP WO2020051493 A5 JPWO2020051493 A5 JP WO2020051493A5 JP 2021512773 A JP2021512773 A JP 2021512773A JP 2021512773 A JP2021512773 A JP 2021512773A JP WO2020051493 A5 JPWO2020051493 A5 JP WO2020051493A5
- Authority
- JP
- Japan
- Prior art keywords
- genetically modified
- cell
- nucleic acid
- modified hematopoietic
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cells Anatomy 0.000 claims 51
- 230000003394 haemopoietic Effects 0.000 claims 44
- 108020004707 nucleic acids Proteins 0.000 claims 27
- 150000007523 nucleic acids Chemical class 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 19
- 102000038129 antigens Human genes 0.000 claims 19
- 108091007172 antigens Proteins 0.000 claims 19
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 17
- 230000011664 signaling Effects 0.000 claims 14
- 102100019461 CD28 Human genes 0.000 claims 9
- 101700033362 CD28 Proteins 0.000 claims 9
- 108020001747 chimeric receptor Proteins 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- -1 kappa chain Proteins 0.000 claims 8
- 230000000139 costimulatory Effects 0.000 claims 7
- 102100009537 TNFRSF9 Human genes 0.000 claims 6
- 101710040535 TNFRSF9 Proteins 0.000 claims 6
- 210000002865 immune cell Anatomy 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 4
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 claims 4
- 230000001086 cytosolic Effects 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- 101700050207 mctC Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 3
- 102100008191 CD8A Human genes 0.000 claims 3
- 101700054655 CD8A Proteins 0.000 claims 3
- 101710040448 TNFRSF4 Proteins 0.000 claims 3
- 102100013135 TNFRSF4 Human genes 0.000 claims 3
- 230000001105 regulatory Effects 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 101700056583 CD27 Proteins 0.000 claims 2
- 102100019459 CD27 Human genes 0.000 claims 2
- 102100013180 KDR Human genes 0.000 claims 2
- 101710030888 KDR Proteins 0.000 claims 2
- 101700039980 L1CAM Proteins 0.000 claims 2
- 102100005613 LDHA Human genes 0.000 claims 2
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims 2
- 101700044345 PDE7A Proteins 0.000 claims 2
- 108091008153 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 230000001717 pathogenic Effects 0.000 claims 2
- 244000052769 pathogens Species 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-N-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-N,1-N-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 108060001251 CD34 Proteins 0.000 claims 1
- 102100016492 CD34 Human genes 0.000 claims 1
- 102100013077 CD4 Human genes 0.000 claims 1
- 101700022938 CD4 Proteins 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 102100005828 CD5 Human genes 0.000 claims 1
- 101700066525 CD5 Proteins 0.000 claims 1
- 102100019453 CD7 Human genes 0.000 claims 1
- 101700063101 CD7 Proteins 0.000 claims 1
- 102100005830 CD70 Human genes 0.000 claims 1
- 101700017377 CD70 Proteins 0.000 claims 1
- 101710043956 CEACAM5 Proteins 0.000 claims 1
- 101710043948 CEACAM7 Proteins 0.000 claims 1
- 108010088013 Carbonic Anhydrase IX Proteins 0.000 claims 1
- 102000008646 Carbonic Anhydrase IX Human genes 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102100016627 EPHA2 Human genes 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 210000003979 Eosinophils Anatomy 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102100009984 FAP Human genes 0.000 claims 1
- 101710008097 FAP Proteins 0.000 claims 1
- 101700079540 FAS Proteins 0.000 claims 1
- 102100008329 FASN Human genes 0.000 claims 1
- 101710008102 FASN Proteins 0.000 claims 1
- 101710044633 FCER1G Proteins 0.000 claims 1
- 102100007619 FCER1G Human genes 0.000 claims 1
- 102100015540 FCGR1A Human genes 0.000 claims 1
- 101710003440 FCGR1A Proteins 0.000 claims 1
- 101710044640 FCGR2A Proteins 0.000 claims 1
- 101710044641 FCGR2B Proteins 0.000 claims 1
- 102100015544 FCGR2C Human genes 0.000 claims 1
- 101710044642 FCGR2C Proteins 0.000 claims 1
- 101710044656 FCGR3A Proteins 0.000 claims 1
- 102100015541 FCGR3A Human genes 0.000 claims 1
- 101700010580 FLO11 Proteins 0.000 claims 1
- 102100008453 FOLH1 Human genes 0.000 claims 1
- 101700036477 FOLH1 Proteins 0.000 claims 1
- 102100011898 FOLR1 Human genes 0.000 claims 1
- 101700050183 FOLR1 Proteins 0.000 claims 1
- 101710037116 GAPC3 Proteins 0.000 claims 1
- 101700053916 GLMN Proteins 0.000 claims 1
- 102100007996 GPC3 Human genes 0.000 claims 1
- 101700044749 GPC3 Proteins 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100016385 HAVCR1 Human genes 0.000 claims 1
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims 1
- 102100004549 IL13RA2 Human genes 0.000 claims 1
- 101710034342 IL13RA2 Proteins 0.000 claims 1
- 102100018760 IL3RA Human genes 0.000 claims 1
- 101700029869 IL3RA Proteins 0.000 claims 1
- 101710036390 KLRK1 Proteins 0.000 claims 1
- 102100012223 KLRK1 Human genes 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 108060004660 MCTS1 Proteins 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 102100006037 MUC1 Human genes 0.000 claims 1
- 101700052761 MUC1 Proteins 0.000 claims 1
- 101700008449 MUC16 Proteins 0.000 claims 1
- 102100006044 MUC16 Human genes 0.000 claims 1
- 210000002540 Macrophages Anatomy 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 210000000440 Neutrophils Anatomy 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 101700011770 PDK1 Proteins 0.000 claims 1
- 102100014458 PDK1 Human genes 0.000 claims 1
- 101700033975 PROM1 Proteins 0.000 claims 1
- 101700038464 PSCA Proteins 0.000 claims 1
- 102100017963 PSCA Human genes 0.000 claims 1
- 102100002896 PSG2 Human genes 0.000 claims 1
- 101700004495 PSG2 Proteins 0.000 claims 1
- 101700008337 PSMA Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 102100017729 ROR1 Human genes 0.000 claims 1
- 101710036428 ROR1 Proteins 0.000 claims 1
- 101700058902 RORA Proteins 0.000 claims 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 1
- 102100010587 SDC1 Human genes 0.000 claims 1
- 101700070405 SDC1 Proteins 0.000 claims 1
- 102100013955 SLC16A1 Human genes 0.000 claims 1
- 102100007163 SLC16A3 Human genes 0.000 claims 1
- 101710032195 SLC16A3 Proteins 0.000 claims 1
- 101710032196 SLC16A4 Proteins 0.000 claims 1
- 102100007168 SLC16A7 Human genes 0.000 claims 1
- 101710032189 SLC16A7 Proteins 0.000 claims 1
- 108060008273 TIMELESS Proteins 0.000 claims 1
- 102100008790 TNFRSF14 Human genes 0.000 claims 1
- 101710038603 TNFRSF18 Proteins 0.000 claims 1
- 102100003096 TNFRSF18 Human genes 0.000 claims 1
- 101710040533 TNFRSF8 Proteins 0.000 claims 1
- 102100009538 TNFRSF8 Human genes 0.000 claims 1
- 101710010287 YWHAZ Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 102000003735 mesothelin Human genes 0.000 claims 1
- 108090000015 mesothelin Proteins 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728306P | 2018-09-07 | 2018-09-07 | |
| US201862728338P | 2018-09-07 | 2018-09-07 | |
| US62/728,306 | 2018-09-07 | ||
| US62/728,338 | 2018-09-07 | ||
| PCT/US2019/050013 WO2020051493A1 (fr) | 2018-09-07 | 2019-09-06 | Polypeptides récepteurs chimériques en association avec des molécules métaboliques trans modulant des concentrations intracellulaires en lactate et utilisations thérapeutiques associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021536265A JP2021536265A (ja) | 2021-12-27 |
| JPWO2020051493A5 true JPWO2020051493A5 (fr) | 2022-09-14 |
Family
ID=69722785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512773A Pending JP2021536265A (ja) | 2018-09-07 | 2019-09-06 | 細胞内乳酸濃度を調節するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210340219A1 (fr) |
| EP (1) | EP3847260A4 (fr) |
| JP (1) | JP2021536265A (fr) |
| KR (1) | KR20210056377A (fr) |
| CN (1) | CN112888786A (fr) |
| AU (1) | AU2019336229A1 (fr) |
| CA (1) | CA3111706A1 (fr) |
| IL (1) | IL281294A (fr) |
| WO (1) | WO2020051493A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3104862A1 (fr) * | 2018-07-03 | 2020-01-09 | Sotio, LLC | Recepteurs chimeriques en association avec des molecules de metabolisme trans ameliorant l'importation de glucose et leurs utilisations therapeutiques |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| BR112022024228A2 (pt) * | 2020-06-04 | 2023-02-07 | Carisma Therapeutics Inc | Construtos para receptores de antígeno quiméricos |
| WO2021252917A2 (fr) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Procédés et compositions de prévention du diabète de type 1 |
| MX2023012760A (es) * | 2021-04-30 | 2023-11-13 | Cellectis Sa | Nuevos cars anti-muc1 y celulas inmunitarias editadas geneticamente para inmunoterapia contra el cancer de tumores solidos. |
| WO2023091909A1 (fr) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Traitement de patients atteints de liposarcome myxoïde/à cellules rondes |
| WO2023144820A1 (fr) * | 2022-01-25 | 2023-08-03 | Ramot At Tel-Aviv University Ltd. | Ingénierie de lymphocytes b pour exprimer des récepteurs antigéniques chimériques (car) et leurs utilisations pour une activation indépendante des lymphocytes t |
| CN114410588B (zh) * | 2022-01-29 | 2022-11-04 | 西安电子科技大学 | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 |
| CN114478806B (zh) * | 2022-04-14 | 2022-07-01 | 呈诺再生医学科技(北京)有限公司 | 一种提升免疫细胞杀伤活性的嵌合受体及其应用 |
| WO2024040207A1 (fr) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques |
| WO2024040208A1 (fr) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques |
| CN116286666B (zh) * | 2023-05-15 | 2023-08-04 | 成都云测医学生物技术有限公司 | 滋养层细胞及其制备方法、应用和扩增nk细胞的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2279253T3 (en) * | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| CA2821547A1 (fr) * | 2010-12-29 | 2012-07-05 | Sigma-Aldrich Co. Llc | Cellules dont l'expression des proteines impliquees dans les processus adme et toxicologiques est perturbee |
| CA2836299A1 (fr) * | 2011-04-15 | 2012-10-18 | Genelux Corporation | Souches clonales de virus attenues de la vaccine et leurs procedes d'utilisation |
| CA2945388A1 (fr) * | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Recepteurs d'antigenes chimeres (car) utilises dans un traitement et methodes de fabrication associees |
| EP3828265A1 (fr) * | 2014-06-06 | 2021-06-02 | Bluebird Bio, Inc. | Compositions de lymphocytes t améliorées |
| WO2016090365A1 (fr) * | 2014-12-05 | 2016-06-09 | Dessain Scott Kendall | Molécules liant pdk1 et leurs utilisations |
| AU2016297014B2 (en) * | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017079703A1 (fr) * | 2015-11-05 | 2017-05-11 | Juno Therapeutics, Inc. | Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive |
| JP6735224B2 (ja) * | 2016-01-28 | 2020-08-05 | 花王株式会社 | アストロサイトのグルコース代謝活性化剤 |
| US20190112349A1 (en) * | 2016-03-18 | 2019-04-18 | Unum Therapeutics Inc. | Modified chimeric receptors and uses thereof in immune therapy |
| BR112019000683A2 (pt) * | 2016-07-15 | 2019-04-24 | Poseida Therapeutics Inc | receptores de antígeno quiméricos e métodos para uso |
| WO2018023093A1 (fr) * | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Polypeptides immunomdulateurs et compositions et procédés associés |
| EP3494141A4 (fr) * | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | Identification de vsig3/vista comme nouveau point de contrôle immunitaire et son utilisation en immunothérapie |
| JP7098615B2 (ja) * | 2016-12-05 | 2022-07-11 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| EP3585394A4 (fr) * | 2017-02-23 | 2021-06-30 | Olema Pharmaceuticals, Inc. | Compositions et procédés de régulation de l'activité du système immunitaire |
-
2019
- 2019-09-06 KR KR1020217009807A patent/KR20210056377A/ko active Search and Examination
- 2019-09-06 EP EP19857632.4A patent/EP3847260A4/fr active Pending
- 2019-09-06 CA CA3111706A patent/CA3111706A1/fr active Pending
- 2019-09-06 AU AU2019336229A patent/AU2019336229A1/en active Pending
- 2019-09-06 JP JP2021512773A patent/JP2021536265A/ja active Pending
- 2019-09-06 US US17/274,021 patent/US20210340219A1/en active Pending
- 2019-09-06 WO PCT/US2019/050013 patent/WO2020051493A1/fr unknown
- 2019-09-06 CN CN201980067513.5A patent/CN112888786A/zh active Pending
-
2021
- 2021-03-07 IL IL281294A patent/IL281294A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220002401A1 (en) | Chimeric antigen receptor and its use | |
| RU2747733C1 (ru) | Терапевтические средства | |
| JP7490915B2 (ja) | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 | |
| Nolan et al. | Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA | |
| Zhao et al. | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity | |
| Stone et al. | A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs) | |
| TWI781117B (zh) | 基於cereblon之異二聚化之嵌合抗原受體 | |
| US20190023764A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| Chmielewski et al. | T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity | |
| Sutherland et al. | ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15 | |
| WO2017219937A1 (fr) | Cellule car-t pour exprimer de manière efficace et stable un anticorps inhibiteur, et application associée | |
| JP2022109975A5 (fr) | ||
| JP2019068822A5 (fr) | ||
| Fry et al. | T-cell adoptive immunotherapy for acute lymphoblastic leukemia | |
| JP2024023228A5 (fr) | ||
| JPWO2020051493A5 (fr) | ||
| US10023648B2 (en) | Anti-TOSO chimeric antigen receptor and its use | |
| WO2023020423A1 (fr) | Cellules car t double ror1/cd19 ou car ror1 pour traiter des tumeurs | |
| WO2021008610A1 (fr) | Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations | |
| US20210070831A1 (en) | Pooling signaling and costimulatory domains in flexible car design | |
| JPWO2019157533A5 (fr) | ||
| JPWO2020010110A5 (fr) | ||
| JPWO2020037066A5 (fr) | ||
| JP2022548468A (ja) | Ｃａｒ－ｃｄ１２３ベクター及びその使用 | |
| Han et al. | Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective |